Relapsed Hodgkin lymphoma in older patients : a comprehensive analysis from the German Hodgkin Study Group
Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Böll, Boris - 1978- [verfasserIn] Goergen, Helen [verfasserIn] Arndt, Nils [verfasserIn] Meißner, Julia [verfasserIn] Krause, Stefan W. [verfasserIn] Schnell, Roland [verfasserIn] von Tresckow, Bastian [verfasserIn] Eichenauer, Dennis A. [verfasserIn] Sasse, Stephanie [verfasserIn] Fuchs, Michael [verfasserIn] Behringer, Karolin [verfasserIn] Klimm, Beate C. [verfasserIn] Naumann, Ralph [verfasserIn] Diehl, Volker [verfasserIn] Engert, Andreas [verfasserIn] Borchmann, Peter [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
November 04, 2013 |
|---|
| Anmerkung: |
Gesehen am 27.11.2020 |
|---|---|
| Umfang: |
7 |
| Übergeordnetes Werk: |
Enthalten in: Journal of clinical oncology - Alexandria, Va. : American Society of Clinical Oncology, 1983, 31(2013), 35, Seite 4431-4437 |
|---|---|
| Übergeordnetes Werk: |
volume:31 ; year:2013 ; number:35 ; pages:4431-4437 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1200/JCO.2013.49.8246 |
|---|
| Katalog-ID: |
1741405009 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1741405009 | ||
| 003 | DE-627 | ||
| 005 | 20230428021816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201127s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2013.49.8246 |2 doi | |
| 035 | |a (DE-627)1741405009 | ||
| 035 | |a (DE-599)KXP1741405009 | ||
| 035 | |a (OCoLC)1341382810 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Böll, Boris |d 1978- |e verfasserin |0 (DE-588)132030543 |0 (DE-627)690316828 |0 (DE-576)298904268 |4 aut | |
| 245 | 1 | 0 | |a Relapsed Hodgkin lymphoma in older patients |b a comprehensive analysis from the German Hodgkin Study Group |c Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann |
| 264 | 1 | |c November 04, 2013 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.11.2020 | ||
| 520 | |a Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. | ||
| 700 | 1 | |a Goergen, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Arndt, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Meißner, Julia |e verfasserin |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 700 | 1 | |a Krause, Stefan W. |e verfasserin |4 aut | |
| 700 | 1 | |a Schnell, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a von Tresckow, Bastian |e verfasserin |4 aut | |
| 700 | 1 | |a Eichenauer, Dennis A. |e verfasserin |4 aut | |
| 700 | 1 | |a Sasse, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Behringer, Karolin |e verfasserin |4 aut | |
| 700 | 1 | |a Klimm, Beate C. |e verfasserin |4 aut | |
| 700 | 1 | |a Naumann, Ralph |e verfasserin |4 aut | |
| 700 | 1 | |a Diehl, Volker |e verfasserin |4 aut | |
| 700 | 1 | |a Engert, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Borchmann, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 31(2013), 35, Seite 4431-4437 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2013 |g number:35 |g pages:4431-4437 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2013.49.8246 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2013.49.8246 |x Verlag |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2013 |e 35 |h 4431-4437 |g 7 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3814688023 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 27-11-20 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2013 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_16 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_7 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1504263340 |a Meißner, Julia | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_4 | ||
| author_variant |
b b bb h g hg n a na j m jm s w k sw swk r s rs t b v tb tbv d a e da dae s s ss m f mf k b kb b c k bc bck r n rn v d vd a e ae p b pb |
|---|---|
| matchkey_str |
article:15277755:2013----::easdogilmhmio |
| oclc_num |
1341382810 |
| hierarchy_sort_str |
November 04, 2013 |
| publishDate |
2013 |
| allfields |
10.1200/JCO.2013.49.8246 doi (DE-627)1741405009 (DE-599)KXP1741405009 (OCoLC)1341382810 DE-627 ger DE-627 rda eng Böll, Boris 1978- verfasserin (DE-588)132030543 (DE-627)690316828 (DE-576)298904268 aut Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann November 04, 2013 7 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 27.11.2020 Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Goergen, Helen verfasserin aut Arndt, Nils verfasserin aut Meißner, Julia verfasserin (DE-588)1236765966 (DE-627)176254850X aut Krause, Stefan W. verfasserin aut Schnell, Roland verfasserin aut von Tresckow, Bastian verfasserin aut Eichenauer, Dennis A. verfasserin aut Sasse, Stephanie verfasserin aut Fuchs, Michael verfasserin aut Behringer, Karolin verfasserin aut Klimm, Beate C. verfasserin aut Naumann, Ralph verfasserin aut Diehl, Volker verfasserin aut Engert, Andreas verfasserin aut Borchmann, Peter verfasserin aut Enthalten in Journal of clinical oncology Alexandria, Va. : American Society of Clinical Oncology, 1983 31(2013), 35, Seite 4431-4437 Online-Ressource (DE-627)313116962 (DE-600)2005181-5 (DE-576)090887018 1527-7755 nnns volume:31 year:2013 number:35 pages:4431-4437 extent:7 https://doi.org/10.1200/JCO.2013.49.8246 Verlag Resolving-System lizenzpflichtig Volltext https://ascopubs.org/doi/10.1200/JCO.2013.49.8246 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_2424 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2013 35 4431-4437 7 2013 01 DE-16-250 3814688023 00 --%%-- --%%-- --%%-- --%%-- l01 27-11-20 2013 01 DE-16-250 00 s hd2013 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_16 2013 01 DE-16-250 03 s s_7 2013 01 DE-16-250 04 p (DE-627)1504263340 Meißner, Julia 2013 01 DE-16-250 04 k (DE-627)1416740783 Medizinische Universitätsklinik und Poliklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_4 |
| spelling |
10.1200/JCO.2013.49.8246 doi (DE-627)1741405009 (DE-599)KXP1741405009 (OCoLC)1341382810 DE-627 ger DE-627 rda eng Böll, Boris 1978- verfasserin (DE-588)132030543 (DE-627)690316828 (DE-576)298904268 aut Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann November 04, 2013 7 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 27.11.2020 Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Goergen, Helen verfasserin aut Arndt, Nils verfasserin aut Meißner, Julia verfasserin (DE-588)1236765966 (DE-627)176254850X aut Krause, Stefan W. verfasserin aut Schnell, Roland verfasserin aut von Tresckow, Bastian verfasserin aut Eichenauer, Dennis A. verfasserin aut Sasse, Stephanie verfasserin aut Fuchs, Michael verfasserin aut Behringer, Karolin verfasserin aut Klimm, Beate C. verfasserin aut Naumann, Ralph verfasserin aut Diehl, Volker verfasserin aut Engert, Andreas verfasserin aut Borchmann, Peter verfasserin aut Enthalten in Journal of clinical oncology Alexandria, Va. : American Society of Clinical Oncology, 1983 31(2013), 35, Seite 4431-4437 Online-Ressource (DE-627)313116962 (DE-600)2005181-5 (DE-576)090887018 1527-7755 nnns volume:31 year:2013 number:35 pages:4431-4437 extent:7 https://doi.org/10.1200/JCO.2013.49.8246 Verlag Resolving-System lizenzpflichtig Volltext https://ascopubs.org/doi/10.1200/JCO.2013.49.8246 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_2424 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2013 35 4431-4437 7 2013 01 DE-16-250 3814688023 00 --%%-- --%%-- --%%-- --%%-- l01 27-11-20 2013 01 DE-16-250 00 s hd2013 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_16 2013 01 DE-16-250 03 s s_7 2013 01 DE-16-250 04 p (DE-627)1504263340 Meißner, Julia 2013 01 DE-16-250 04 k (DE-627)1416740783 Medizinische Universitätsklinik und Poliklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_4 |
| allfields_unstemmed |
10.1200/JCO.2013.49.8246 doi (DE-627)1741405009 (DE-599)KXP1741405009 (OCoLC)1341382810 DE-627 ger DE-627 rda eng Böll, Boris 1978- verfasserin (DE-588)132030543 (DE-627)690316828 (DE-576)298904268 aut Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann November 04, 2013 7 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 27.11.2020 Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Goergen, Helen verfasserin aut Arndt, Nils verfasserin aut Meißner, Julia verfasserin (DE-588)1236765966 (DE-627)176254850X aut Krause, Stefan W. verfasserin aut Schnell, Roland verfasserin aut von Tresckow, Bastian verfasserin aut Eichenauer, Dennis A. verfasserin aut Sasse, Stephanie verfasserin aut Fuchs, Michael verfasserin aut Behringer, Karolin verfasserin aut Klimm, Beate C. verfasserin aut Naumann, Ralph verfasserin aut Diehl, Volker verfasserin aut Engert, Andreas verfasserin aut Borchmann, Peter verfasserin aut Enthalten in Journal of clinical oncology Alexandria, Va. : American Society of Clinical Oncology, 1983 31(2013), 35, Seite 4431-4437 Online-Ressource (DE-627)313116962 (DE-600)2005181-5 (DE-576)090887018 1527-7755 nnns volume:31 year:2013 number:35 pages:4431-4437 extent:7 https://doi.org/10.1200/JCO.2013.49.8246 Verlag Resolving-System lizenzpflichtig Volltext https://ascopubs.org/doi/10.1200/JCO.2013.49.8246 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_2424 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2013 35 4431-4437 7 2013 01 DE-16-250 3814688023 00 --%%-- --%%-- --%%-- --%%-- l01 27-11-20 2013 01 DE-16-250 00 s hd2013 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_16 2013 01 DE-16-250 03 s s_7 2013 01 DE-16-250 04 p (DE-627)1504263340 Meißner, Julia 2013 01 DE-16-250 04 k (DE-627)1416740783 Medizinische Universitätsklinik und Poliklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_4 |
| allfieldsGer |
10.1200/JCO.2013.49.8246 doi (DE-627)1741405009 (DE-599)KXP1741405009 (OCoLC)1341382810 DE-627 ger DE-627 rda eng Böll, Boris 1978- verfasserin (DE-588)132030543 (DE-627)690316828 (DE-576)298904268 aut Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann November 04, 2013 7 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 27.11.2020 Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Goergen, Helen verfasserin aut Arndt, Nils verfasserin aut Meißner, Julia verfasserin (DE-588)1236765966 (DE-627)176254850X aut Krause, Stefan W. verfasserin aut Schnell, Roland verfasserin aut von Tresckow, Bastian verfasserin aut Eichenauer, Dennis A. verfasserin aut Sasse, Stephanie verfasserin aut Fuchs, Michael verfasserin aut Behringer, Karolin verfasserin aut Klimm, Beate C. verfasserin aut Naumann, Ralph verfasserin aut Diehl, Volker verfasserin aut Engert, Andreas verfasserin aut Borchmann, Peter verfasserin aut Enthalten in Journal of clinical oncology Alexandria, Va. : American Society of Clinical Oncology, 1983 31(2013), 35, Seite 4431-4437 Online-Ressource (DE-627)313116962 (DE-600)2005181-5 (DE-576)090887018 1527-7755 nnns volume:31 year:2013 number:35 pages:4431-4437 extent:7 https://doi.org/10.1200/JCO.2013.49.8246 Verlag Resolving-System lizenzpflichtig Volltext https://ascopubs.org/doi/10.1200/JCO.2013.49.8246 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_2424 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2013 35 4431-4437 7 2013 01 DE-16-250 3814688023 00 --%%-- --%%-- --%%-- --%%-- l01 27-11-20 2013 01 DE-16-250 00 s hd2013 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_16 2013 01 DE-16-250 03 s s_7 2013 01 DE-16-250 04 p (DE-627)1504263340 Meißner, Julia 2013 01 DE-16-250 04 k (DE-627)1416740783 Medizinische Universitätsklinik und Poliklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_4 |
| allfieldsSound |
10.1200/JCO.2013.49.8246 doi (DE-627)1741405009 (DE-599)KXP1741405009 (OCoLC)1341382810 DE-627 ger DE-627 rda eng Böll, Boris 1978- verfasserin (DE-588)132030543 (DE-627)690316828 (DE-576)298904268 aut Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann November 04, 2013 7 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 27.11.2020 Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Goergen, Helen verfasserin aut Arndt, Nils verfasserin aut Meißner, Julia verfasserin (DE-588)1236765966 (DE-627)176254850X aut Krause, Stefan W. verfasserin aut Schnell, Roland verfasserin aut von Tresckow, Bastian verfasserin aut Eichenauer, Dennis A. verfasserin aut Sasse, Stephanie verfasserin aut Fuchs, Michael verfasserin aut Behringer, Karolin verfasserin aut Klimm, Beate C. verfasserin aut Naumann, Ralph verfasserin aut Diehl, Volker verfasserin aut Engert, Andreas verfasserin aut Borchmann, Peter verfasserin aut Enthalten in Journal of clinical oncology Alexandria, Va. : American Society of Clinical Oncology, 1983 31(2013), 35, Seite 4431-4437 Online-Ressource (DE-627)313116962 (DE-600)2005181-5 (DE-576)090887018 1527-7755 nnns volume:31 year:2013 number:35 pages:4431-4437 extent:7 https://doi.org/10.1200/JCO.2013.49.8246 Verlag Resolving-System lizenzpflichtig Volltext https://ascopubs.org/doi/10.1200/JCO.2013.49.8246 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_2424 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2013 35 4431-4437 7 2013 01 DE-16-250 3814688023 00 --%%-- --%%-- --%%-- --%%-- l01 27-11-20 2013 01 DE-16-250 00 s hd2013 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_16 2013 01 DE-16-250 03 s s_7 2013 01 DE-16-250 04 p (DE-627)1504263340 Meißner, Julia 2013 01 DE-16-250 04 k (DE-627)1416740783 Medizinische Universitätsklinik und Poliklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_4 |
| language |
English |
| source |
Enthalten in Journal of clinical oncology 31(2013), 35, Seite 4431-4437 volume:31 year:2013 number:35 pages:4431-4437 extent:7 |
| sourceStr |
Enthalten in Journal of clinical oncology 31(2013), 35, Seite 4431-4437 volume:31 year:2013 number:35 pages:4431-4437 extent:7 |
| format_phy_str_mv |
Article |
| building |
2013:0 |
| institution |
findex.gbv.de |
| selectbib_iln_str_mv |
2013@01 |
| sw_local_iln_str_mv |
2013:hd2013 DE-16-250:hd2013 2013:wissenschaftlicher Artikel (Zeitschrift) DE-16-250:wissenschaftlicher Artikel (Zeitschrift) 2013:per_16 DE-16-250:per_16 2013:s_7 DE-16-250:s_7 2013:Meißner, Julia DE-16-250:Meißner, Julia 2013:Medizinische Universitätsklinik und Poliklinik DE-16-250:Medizinische Universitätsklinik und Poliklinik 2013:Verfasser DE-16-250:Verfasser 2013:pos_4 DE-16-250:pos_4 |
| isfreeaccess_bool |
false |
| container_title |
Journal of clinical oncology |
| authorswithroles_txt_mv |
Böll, Boris @@aut@@ Goergen, Helen @@aut@@ Arndt, Nils @@aut@@ Meißner, Julia @@aut@@ Krause, Stefan W. @@aut@@ Schnell, Roland @@aut@@ von Tresckow, Bastian @@aut@@ Eichenauer, Dennis A. @@aut@@ Sasse, Stephanie @@aut@@ Fuchs, Michael @@aut@@ Behringer, Karolin @@aut@@ Klimm, Beate C. @@aut@@ Naumann, Ralph @@aut@@ Diehl, Volker @@aut@@ Engert, Andreas @@aut@@ Borchmann, Peter @@aut@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
313116962 |
| id |
1741405009 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1741405009</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230428021816.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201127s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1200/JCO.2013.49.8246</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1741405009</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KXP1741405009</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1341382810</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Böll, Boris</subfield><subfield code="d">1978-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)132030543</subfield><subfield code="0">(DE-627)690316828</subfield><subfield code="0">(DE-576)298904268</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Relapsed Hodgkin lymphoma in older patients</subfield><subfield code="b">a comprehensive analysis from the German Hodgkin Study Group</subfield><subfield code="c">Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">November 04, 2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Gesehen am 27.11.2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goergen, Helen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arndt, Nils</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meißner, Julia</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1236765966</subfield><subfield code="0">(DE-627)176254850X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krause, Stefan W.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schnell, Roland</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Tresckow, Bastian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eichenauer, Dennis A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sasse, Stephanie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fuchs, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Behringer, Karolin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klimm, Beate C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naumann, Ralph</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Diehl, Volker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Engert, Andreas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borchmann, Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of clinical oncology</subfield><subfield code="d">Alexandria, Va. : American Society of Clinical Oncology, 1983</subfield><subfield code="g">31(2013), 35, Seite 4431-4437</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)313116962</subfield><subfield code="w">(DE-600)2005181-5</subfield><subfield code="w">(DE-576)090887018</subfield><subfield code="x">1527-7755</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:35</subfield><subfield code="g">pages:4431-4437</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1200/JCO.2013.49.8246</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ascopubs.org/doi/10.1200/JCO.2013.49.8246</subfield><subfield code="x">Verlag</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2424</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2013</subfield><subfield code="e">35</subfield><subfield code="h">4431-4437</subfield><subfield code="g">7</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">3814688023</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">27-11-20</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2013</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_16</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_7</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1504263340</subfield><subfield code="a">Meißner, Julia</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416740783</subfield><subfield code="a">Medizinische Universitätsklinik und Poliklinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_4</subfield></datafield></record></collection>
|
| standort_str_mv |
--%%-- |
| standort_iln_str_mv |
2013:--%%-- DE-16-250:--%%-- |
| author |
Böll, Boris 1978- |
| spellingShingle |
Böll, Boris 1978- 2013 hd2013 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_16 2013 s_7 2013 Meißner, Julia 2013 Medizinische Universitätsklinik und Poliklinik 2013 Verfasser 2013 pos_4 Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group |
| authorStr |
Böll, Boris 1978- |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)313116962 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| typewithnormlink_str_mv |
DifferentiatedPerson@(DE-588)132030543 Person@(DE-588)132030543 Person@(DE-588)1236765966 DifferentiatedPerson@(DE-588)1236765966 |
| collection |
KXP SWB GVK |
| remote_str |
true |
| last_changed_iln_str_mv |
2013@27-11-20 |
| illustrated |
Not Illustrated |
| issn |
1527-7755 |
| topic_title |
2013 01 DE-16-250 00 s hd2013 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_16 2013 01 DE-16-250 03 s s_7 2013 01 DE-16-250 04 p (DE-627)1504263340 Meißner, Julia 2013 01 DE-16-250 04 k (DE-627)1416740783 Medizinische Universitätsklinik und Poliklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_4 Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann |
| topic |
2013 hd2013 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_16 2013 s_7 2013 Meißner, Julia 2013 Medizinische Universitätsklinik und Poliklinik 2013 Verfasser 2013 pos_4 |
| topic_unstemmed |
2013 hd2013 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_16 2013 s_7 2013 Meißner, Julia 2013 Medizinische Universitätsklinik und Poliklinik 2013 Verfasser 2013 pos_4 |
| topic_browse |
2013 hd2013 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_16 2013 s_7 2013 Meißner, Julia 2013 Medizinische Universitätsklinik und Poliklinik 2013 Verfasser 2013 pos_4 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| standort_txtP_mv |
--%%-- |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of clinical oncology |
| normlinkwithtype_str_mv |
(DE-588)132030543@DifferentiatedPerson (DE-588)132030543@Person (DE-588)1236765966@Person (DE-588)1236765966@DifferentiatedPerson |
| hierarchy_parent_id |
313116962 |
| signature |
--%%-- |
| signature_str_mv |
--%%-- |
| hierarchy_top_title |
Journal of clinical oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)313116962 (DE-600)2005181-5 (DE-576)090887018 |
| normlinkwithrole_str_mv |
(DE-588)132030543@@aut@@ (DE-588)1236765966@@aut@@ |
| title |
Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group |
| ctrlnum |
(DE-627)1741405009 (DE-599)KXP1741405009 (OCoLC)1341382810 |
| title_full |
Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann |
| author_sort |
Böll, Boris 1978- |
| journal |
Journal of clinical oncology |
| journalStr |
Journal of clinical oncology |
| callnumber-first-code |
- |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
txt |
| container_start_page |
4431 |
| author_browse |
Böll, Boris Goergen, Helen Arndt, Nils Meißner, Julia Krause, Stefan W. Schnell, Roland von Tresckow, Bastian Eichenauer, Dennis A. Sasse, Stephanie Fuchs, Michael Behringer, Karolin Klimm, Beate C. Naumann, Ralph Diehl, Volker Engert, Andreas Borchmann, Peter |
| selectkey |
2013:l |
| container_volume |
31 |
| physical |
7 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Böll, Boris |
| title_sub |
a comprehensive analysis from the German Hodgkin Study Group |
| doi_str_mv |
10.1200/JCO.2013.49.8246 |
| normlink |
132030543 690316828 298904268 1236765966 176254850X 1410508463 1504263340 1416740783 1410501914 |
| normlink_prefix_str_mv |
(DE-588)132030543 (DE-627)690316828 (DE-576)298904268 (DE-588)1236765966 (DE-627)176254850X (DE-627)1410508463 (DE-627)1504263340 (DE-627)1416740783 (DE-627)1410501914 |
| author2-role |
verfasserin |
| title_sort |
relapsed hodgkin lymphoma in older patientsa comprehensive analysis from the german hodgkin study group |
| title_auth |
Relapsed Hodgkin lymphoma in older patients a comprehensive analysis from the German Hodgkin Study Group |
| abstract |
Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Gesehen am 27.11.2020 |
| abstractGer |
Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Gesehen am 27.11.2020 |
| abstract_unstemmed |
Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients. Gesehen am 27.11.2020 |
| collection_details |
GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_2424 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
35 |
| title_short |
Relapsed Hodgkin lymphoma in older patients |
| url |
https://doi.org/10.1200/JCO.2013.49.8246 https://ascopubs.org/doi/10.1200/JCO.2013.49.8246 |
| ausleihindikator_str_mv |
2013:- |
| rolewithnormlink_str_mv |
@@aut@@(DE-588)132030543 @@aut@@(DE-588)1236765966 |
| remote_bool |
true |
| author2 |
Goergen, Helen Arndt, Nils Meißner, Julia Krause, Stefan W. Schnell, Roland von Tresckow, Bastian Eichenauer, Dennis A. Sasse, Stephanie Fuchs, Michael Behringer, Karolin Klimm, Beate C. Naumann, Ralph Diehl, Volker Engert, Andreas Borchmann, Peter |
| author2Str |
Goergen, Helen Arndt, Nils Meißner, Julia Krause, Stefan W. Schnell, Roland von Tresckow, Bastian Eichenauer, Dennis A. Sasse, Stephanie Fuchs, Michael Behringer, Karolin Klimm, Beate C. Naumann, Ralph Diehl, Volker Engert, Andreas Borchmann, Peter |
| ppnlink |
313116962 |
| GND_str_mv |
Böll, B. Böll, Boris Meissner, J. Meißner, J. Meissner, Julia Meißner, Julia |
| GND_txt_mv |
Böll, B. Böll, Boris Meissner, J. Meißner, J. Meissner, Julia Meißner, Julia |
| GND_txtF_mv |
Böll, B. Böll, Boris Meissner, J. Meißner, J. Meissner, Julia Meißner, Julia |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1200/JCO.2013.49.8246 |
| callnumber-a |
--%%-- |
| up_date |
2024-07-04T17:38:26.985Z |
| _version_ |
1803670998994649088 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1741405009</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230428021816.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201127s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1200/JCO.2013.49.8246</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1741405009</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KXP1741405009</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1341382810</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Böll, Boris</subfield><subfield code="d">1978-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)132030543</subfield><subfield code="0">(DE-627)690316828</subfield><subfield code="0">(DE-576)298904268</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Relapsed Hodgkin lymphoma in older patients</subfield><subfield code="b">a comprehensive analysis from the German Hodgkin Study Group</subfield><subfield code="c">Boris Böll, Helen Goergen, Nils Arndt, Julia Meissner, Stefan W. Krause, Roland Schnell, Bastian von Tresckow, Dennis A. Eichenauer, Stephanie Sasse, Michael Fuchs, Karolin Behringer, Beate C. Klimm, Ralph Naumann, Volker Diehl, Andreas Engert, and Peter Borchmann</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">November 04, 2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Gesehen am 27.11.2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goergen, Helen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arndt, Nils</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meißner, Julia</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1236765966</subfield><subfield code="0">(DE-627)176254850X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krause, Stefan W.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schnell, Roland</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Tresckow, Bastian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eichenauer, Dennis A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sasse, Stephanie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fuchs, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Behringer, Karolin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klimm, Beate C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naumann, Ralph</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Diehl, Volker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Engert, Andreas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borchmann, Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of clinical oncology</subfield><subfield code="d">Alexandria, Va. : American Society of Clinical Oncology, 1983</subfield><subfield code="g">31(2013), 35, Seite 4431-4437</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)313116962</subfield><subfield code="w">(DE-600)2005181-5</subfield><subfield code="w">(DE-576)090887018</subfield><subfield code="x">1527-7755</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:35</subfield><subfield code="g">pages:4431-4437</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1200/JCO.2013.49.8246</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ascopubs.org/doi/10.1200/JCO.2013.49.8246</subfield><subfield code="x">Verlag</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2424</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2013</subfield><subfield code="e">35</subfield><subfield code="h">4431-4437</subfield><subfield code="g">7</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">3814688023</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">27-11-20</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2013</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_16</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_7</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1504263340</subfield><subfield code="a">Meißner, Julia</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416740783</subfield><subfield code="a">Medizinische Universitätsklinik und Poliklinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_4</subfield></datafield></record></collection>
|
| score |
7.401944 |